Aura Biosciences, Inc. (AURA)
- Previous Close
10.07 - Open
9.93 - Bid 9.93 x 400
- Ask 10.03 x 100
- Day's Range
9.78 - 10.85 - 52 Week Range
5.99 - 12.35 - Volume
334,372 - Avg. Volume
187,533 - Market Cap (intraday)
494.573M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.79 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette?guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
www.aurabiosciences.comRecent News: AURA
View MorePerformance Overview: AURA
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AURA
View MoreValuation Measures
Market Cap
494.57M
Enterprise Value
326.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.48%
Return on Equity (ttm)
-45.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-80.69M
Diluted EPS (ttm)
-1.79
Balance Sheet and Cash Flow
Total Cash (mrq)
187.42M
Total Debt/Equity (mrq)
9.94%
Levered Free Cash Flow (ttm)
-47.31M